MedPage Today (9/9, Monaco) reported, “Youth with attention-deficit/hyperactivity disorder” (AD/HD) “saw mildly different growth trajectories with certain popular medications, researchers reported” in findings presented in a poster at Psych Congress 2023. The study revealed that when “compared with youth prescribed lisdexamfetamine dimesylate (LDX; Vyvanse), those who took delayed release/extended-release methylphenidate (DR/ER-MPH; Jornay PM) saw a greater weight trajectory in the first year after starting treatment.” Included in the final study sample were “83 patients on DR/ER-MPH, 240 on OROS MPH, and 403 on LDX.”
Related Links:
— MedPage Today (requires login and subscription)